Effects of an Intrathecal Drug Delivery System Connected to a Subcutaneous Port on Pain, Mood and Quality of Life in End Stage Cancer Patients: An Observational Study

被引:1
作者
Giglio, Mariateresa [1 ]
Preziosa, Angela [1 ]
Mele, Roberta [1 ]
Brienza, Nicola [2 ]
Grasso, Salvatore [3 ]
Puntillo, Filomena [1 ,2 ]
机构
[1] Policlin Hosp, Anaesthesia Intens Care & Pain Unit, Bari, Italy
[2] Univ Bari Aldo Moro, Dept Interdisciplinary Med, Bari, Italy
[3] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Bari, Italy
关键词
cancer pain; morphine; intrathecal therapy; quality of life; depression; anxiety; sleep; COMPREHENSIVE MEDICAL-MANAGEMENT; RETROSPECTIVE ANALYSIS; GUIDELINES; ANALGESIA; TOXICITY; THERAPY;
D O I
10.1177/10732748221133752
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background In cancer patients with limited life expectancy, an implant of an intrathecal (IT) drug delivery system connected to a subcutaneous port (IDDS-SP) has been proposed as a successful strategy, but conflicting results are reported on quality of life (QoL). The aim of this prospective observational study is to report the effects on pain, mood and QoL of an IT combination therapy delivered by an IDDS-SP in malignant refractory pain. Methods Adult patients in which IT therapy was recommended were recruited. An IT therapy with morphine and levobupivacaine was started: VASPI score, depression and anxiety (evaluated by the Edmonton Symptom Assessment System -ESAS-), the Pittsburgh Sleep Quality Index (PSQI), the 5-level EuroQol 5D version (EQ-5D-5L) and the requirements of breakthrough cancer pain (BTcP) medications were registered, with adverse events rate and the satisfaction of patients scored as Patient Global Impression of Change (PGIC). Results Fifty patients, (16 F/34 M) were enrolled (age 69 +/- 12). All had advanced cancer with metastasis. The median daily VASPI score was 75, the median depression score was 6, and the median anxiety score was 4, median PSQI was 16. At 28 days, a significant reduction in VASPI score was registered as well as in depression and anxiety item. Also, PSQI decreased significantly. The EQ-5D-5 L showed a significant improvement in all components at 14 and 28 days. Patient Global Impression of Change scores showed high level of satisfaction. A low incidence of adverse events and a reduction in BTCP episodes were also registered. Conclusion Intrathecal combination therapy delivered by an IDDS-SP could ensure adequate control of cancer related symptoms, such as pain, depression, anxiety and sleep disturbances. These effects, with low rate of AEs and reduced BTcP episodes, could explain the improvement in QoL and the overall high levels of patients' satisfaction.
引用
收藏
页数:8
相关论文
共 29 条
  • [21] The effects of psychosocial and economic factors on the quality of life of patients with end-stage renal disease and their caregivers in Klang Valley, Malaysia: protocol for a mixed-methods study
    Ibrahim, Norhayati
    Chu, Sin Yee
    Siau, Ching Sin
    Amit, Noh
    Ismail, Rozmi
    Gafor, Abdul Halim Abdul
    BMJ OPEN, 2022, 12 (06):
  • [22] Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer An observational study
    Tseng, Li-Chuan
    Chen, Kang-Hua
    Wang, Chih-Liang
    Weng, Li-Chueh
    MEDICINE, 2020, 99 (23)
  • [23] Impact of Gastrointestinal Side Effects on Patients' Reported Quality of Life Trajectories after Radiotherapy for Prostate Cancer: Data from the Prospective, Observational Pros-IT CNR Study
    Noale, Marianna
    Bruni, Alessio
    Triggiani, Luca
    Buglione, Michela
    Bertoni, Filippo
    Frassinelli, Luca
    Montironi, Rodolfo
    Corvo, Renzo
    Zagonel, Vittorina
    Porreca, Angelo
    Bassi, Pierfrancesco
    Gacci, Mauro
    Conti, Giario Natale
    Maggi, Stefania
    Magrini, Stefano
    CANCERS, 2021, 13 (06)
  • [24] Quality of life improves after palliative placement of percutaneous tunneled drainage catheter for refractory ascites in prospective study of patients with end-stage cancer
    Robson, Piera Cote
    Gonen, Mithat
    Ni, Ai
    Brody, Lynn
    Brown, Karen T.
    Getrajdman, George
    Thom, Bridgette
    Kline, Nancy
    Covey, Anne
    PALLIATIVE & SUPPORTIVE CARE, 2019, 17 (06) : 677 - 685
  • [25] Effects of high-dose opioid analgesia on survival, pain relief, quality of life and adverse drug reactions in cancer and neuropathic pain patients: a retrospective cohort study in real-world clinical practice
    Hao, Xing
    Zhou, Yiting
    Ling, Yingxian
    Miyoshi, Hirotsugu
    Sumitani, Masahiko
    Chan, Kwok Ying
    Park, Hue Jung
    Feng, Zhiying
    Rao, Yuefeng
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (18)
  • [26] Prognostic effects of health-related quality of life at baseline and early change in health-related quality of life on response to treatment and survival in patients with advanced lung cancer: a prospective observational study in China
    Liu, Jiali
    Ma, Yuxiang
    Gao, Ruizhen
    Liu, Xia
    Wang, Yalan
    Yu, Juan
    Zhan, Jianhua
    Huang, Yan
    Qin, Huiyin
    Zhang, Li
    BMJ OPEN, 2022, 12 (02):
  • [27] Clinical and Quality of Life Benefits for End-Stage Workers' Compensation Chronic Pain Claimants following H-Wave® Device Stimulation: A Retrospective Observational Study with Mean 2-Year Follow-Up
    Trinh, Alan
    Williamson, Tyler K.
    Han, David
    Hazlewood, Jeffrey E.
    Norwood, Stephen M.
    Gupta, Ashim
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (03)
  • [28] Effects of a mobile oral care app on oral mucositis, pain, nutritional status, and quality of life in patients with head and neck cancer: A quasi-experimental study
    Lin, Tzu-Hsuan
    Wang, Yu-Ming
    Huang, Cheng-Yi
    INTERNATIONAL JOURNAL OF NURSING PRACTICE, 2022, 28 (04)
  • [29] The effect of adjuvant chemotherapy on symptom burden and quality of life over time; a preliminary prospective observational study using individual data of patients aged ≥70 with early stage invasive breast cancer
    Quinten, Chantal
    Kenis, C.
    Hamaker, M.
    Coolbrandt, A.
    Brouwers, B.
    Dal Lago, L.
    Neven, P.
    Vuylsteke, P.
    Debrock, G.
    Van den Bulck, H.
    Smeets, A.
    Schoffski, P.
    Bottomley, A.
    Wedding, U.
    Wildiers, H.
    JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (02) : 152 - 162